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Abstract 
CD8+ T cells provide a critical defence from pathogens at mucosal epithelia including the 
female reproductive tract (FRT). Mucosal immunisation is considered essential to initiate this 
response, however this is difficult to reconcile with evidence that antigen delivered to skin 
can recruit protective CD8+ T cells to mucosal tissues. Here we dissect the underlying 
mechanism. We show that adenovirus serotype 5 (Ad5) bio-distributes at very low level to 
non-lymphoid tissues after skin immunisation. This drives the expansion and activation of 
CD3- NK1.1+ group 1 innate lymphoid cells (ILC1) within the FRT, essential for recruitment of 
CD8+ T-cell effectors. Interferon gamma produced by activated ILC1 is critical to licence 
CD11b+Ly6C+ monocyte production of CXCL9, a chemokine required to recruit skin primed 
CXCR3+ CD8+T-cells to the FRT. Our findings reveal a novel role for ILC1 to recruit effector 
CD8+ T-cells to prevent virus spread and establish immune surveillance at barrier tissues. 
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Introduction 
The majority of pathogens, including HIV, influenza virus and Mycobacterium tuberculosis 
that contribute to the global burden of infectious disease initiate infection at the mucosal 
barrier tissues. At least two sub-sets of memory CD8+ T cells patrol the mucosal tissues as a 
front line defence: a non-recirculating, tissue resident memory (TRM) population of CD8+ T 
cells 1 and an effector memory (TEM)  population of CD8+ T cells that circulate between the 
blood and non-lymphoid tissues 2. These subsets of CD8+ T cells are uniquely poised to 
provide an immediate response, within minutes to hours of pathogen detection at the barrier 
tissues and dictate the outcome of infection.  In direct contrast, circulating central memory 
(TCM) CD8+ T cells require time to enter the tissues and respond to pathogen infection. 
Accordingly, intense interest has focused on immunisation strategies that promote 
recruitment of memory CD8+ T cell subsets to the mucosal epithelial tissues 1,3,4. 
Traditionally, the generation of antigen-specific T cells that manifest defences at the 
epithelial barriers has been viewed as dependent on mucosal routes of vaccination 5-8, and 
priming by antigen–bearing dendritic cells (DCs) at the mucosa and associated draining 
lymphoid tissues 9,10. Such DCs were found to imprint distinct homing molecules that help 
gut/lung activated T cells to efficiently traffic to the anatomic site of pathogen infection or 
immunisation and clear the antigen 11-14. Nonetheless, immunisation by systemic routes 
(intramuscular, subcutaneous and intradermal) with replication defective viral vectors, 
including adenovirus (Ad) and pox viruses can effectively elicit and recruit polyfunctional 
antigen-specific CD8+ T cells to mucosal barrier tissues 15-18. These responses can be long-
lived and confer protection 17. For example, scarification of the skin with vaccinia virus (VV) 
or modified VV Ankara protects from respiratory pathogen challenge in animal models 19,20. 
Importantly in humans, skin scarification with VV remains a classic example of a successful 
vaccination strategy that confers protection against smallpox (variola virus) infection that is 
acquired by the aerosol route 21. These reports would suggest that cutaneous antigen 
exposure does not restrict seeding of antigen experienced CD8+ T cells (effector and 
memory) to the skin.  
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The mechanism/s that enable antigen specific CD8+ T cells to disseminate and acquire 
residence in epithelial barrier tissues remote from the site of immunisation are unclear. While 
it is well acknowledged that CD8+ T cells are programmed to express adhesion and 
chemokine receptors specific to the site of immunisation, emphasising the role of tissue DCs 
in determining T cell trafficking 22,23, alternative mechanisms for CD8+ T cell trafficking must 
exist in parallel to explain T cell dissemination to remote, unrelated tissues. One paradigm 
states that a subset of early effector CD8+ T cells may gain additional homing potential by 
trafficking through distant lymph node (LN) microenvironments, such that T cells originally 
activated in skin draining LNs may acquire gut homing molecules by trafficking through 
mesenteric LNs 24. Equally there is evidence that the spleen engenders early CD8+ T cell 
effectors to acquire a gut homing program though expressed α4β7, though migration to non-
intestinal tissues was not addressed 25.  It is also known that inflammatory signals provided 
by topical chemokine application to the vagina can recruit activated CD8+ T cells from the 
systemic compartment to that tissue and establish a tissue-resident memory pool by a 
‘prime-pull’ strategy 26. However, the capacity of early spleen derived CD8+ T cell effectors to 
migrate to epithelial tissues despite their not being the target of infection and the potential 
crosstalk of innate effectors (including macrophages, innate lymphoid cells and 
unconventional T cells) within the epithelia that may provide signals to recruit CD8+ T cells 
remains unanswered. Given the importance of immune surveillance at the epithelial barrier 
tissues and to reconcile seemingly disparate reports, we set out to gain further insights into 
the mechanism by which skin immunisation generates CD8+ T cells that populate the 
mucosal epithelia.  
Here, we report using a replication defective Ad5 vector encoding HIV-1 CN54 gag (Ad-
CN54 gag) as a candidate vaccine antigen, that skin immunisation generated CD8+ T cells 
that uniformly expressed the chemokine receptor CXCR3 and conferred protection in the 
female reproductive mucosa against a VV challenge encoding the cognate antigen. We 
discovered that following skin immunisation, a low but consistent copy number of vector 
DNA bio-distributed to the female reproductive tract (FRT). Importantly, while this low dose 
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of bio-distributed vector was insufficient to prime CD8+ T cells locally in the FRT, it was 
sufficient to recruit skin primed CXCR3+CD8+ T-cells independent of antigen by CXCL9 (the 
cognate chemokine ligand for CXCR3) produced by CD11b+Ly6C+ monocytes and also 
CD11b+ DC. Cell intrinsic interferon gamma (IFNγ) produced by group 1 innate lymphoid 
cells (ILC1) in the FRT was essential to licence CXCL9 expression and recruit CD8+ T cells 
to the tissue. These results reveal a previously unappreciated role for ILC1 to mobilise 
effector CD8+ T cells to peripheral epithelial tissues and provide a memory pool of tissue-
resident CD8+ T cells to protect the host against infection. 
 
Results 
 
Skin immunisation elicits high frequency CD8 T cells in FRT 
We first investigated the capacity of skin immunisation to generate antigen-specific CD8+ T 
cells that localise in the female reproductive mucosa. As a model system, B6 mice were 
immunised with a relevant vaccine target, a synthetic HIV-1 gag CN54 gene (codon 
optimised for mammalian codon use) and expressed from a replication defective Ad5 vector 
(Ad-CN54 gag) described previously 27. Immunisation was by intradermal injection (ID) and 
by a promising microneedle array (MA) platform progressing through the clinic 27 whose 
immunising properties we reported are dependent on dermal DCs 27.  At 1 X 109 viral 
particles (vp) Ad-CN54 gag, both skin immunisation routes elicited as expected high 
frequency CD8+ T cells tracked by tetramer (Tet) to the immunodominant Db-restricted HIV-1 
CN54 gag308-318 epitope (Db/CN54 gag) 17 in blood, spleen and inguinal LN (Fig. 1a,b,c and 
d). Remarkably, both cutaneous routes of immunisation-elicited high frequency Db/CN54 gag 
Tet+ CD8+ T cells that populated the FRT (Fig. 1d). The lower Ad vector dose (1 X 107 vp) 
applied to the skin, elicited a markedly lower frequency of Db/CN54 gag Tet+ CD8+ T cells 
recruited to the FRT (Supplementary Fig 1) consistent with previous Ad5 vaccination studies 
that report a vector dose-dependence for priming systemic antigen-specific CD8 T cells 27,28. 
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To exclude the possibility that proximity of the immunisation site (back skin) influenced 
accumulation of CD8+ T cells in the female FRT, mice were immunised to the dorsal surface 
of the ear (Fig. 1e). Irrespective of the site of skin immunisation (ear or back) the frequency 
of activated CD11ahiDb/CN54gag Tet+ CD8+ T cells detected in the FRT at day 14-post 
immunisation was statistically indistinguishable (Fig. 1f and g). Having established that skin 
immunisation has the capacity to recruit antigen-specific CD8+ T cells to the FRT, we 
examined if this observation might be extended to IM immunisation, a route commonly used 
in human vaccination. There was a lower, but not-significant difference in frequency of 
CN54gag Tet+ CD8+ T cells recruited to the FTR after IM immunisation when cross-compared 
with skin immunisation (Supplementary Fig 2). Together these data demonstrated that 
antigen-specific CD8+ T cells primed by skin (and also IM) immunisation localise not only in 
lymphoid tissue draining the site of antigen encounter but also in non-lymphoid tissue such 
as the FRT by a mechanism independent of the anatomic site of immunisation or the mode 
antigen delivery. 
Skin primed FRT CD8 T cells protect against VV challenge 
Given that antigen experienced CD8+ αβ+ T cells may express regulatory or cytotoxic effector 
functions in mucosal tissues 29-32 that are acquired during priming 33 we determined whether 
CD8+ T cells localised in the FRT after skin immunisation expressed cytolytic antiviral activity. 
To that end, mice primed with Ad-CN54 gag by ID injection or by MA immunisation were 
challenged by injection into the wall of the vagina on day 14 with carboxyfluorescein 
succinimidyl ester (CFSE)-labelled syngeneic targets pulsed with peptide to the 
immunodominant Db restricted HIV-1 CN54 gag epitope 34 and with control targets. 
Cytotoxicity of CFSE-labelled donor cells isolated from the vagina was analysed after 18 h by 
flow cytometry (Fig. 2a). Robust antigen-specific in vivo killing was observed in the vagina of 
mice 14 days after skin immunisation (either ID or by MA) (Fig. 2b and c).  Furthermore, flow 
cytometry of cells isolated from the FRT tissue of immunised mice, when re-stimulated in 
vitro with peptide to the immunodominant Db restricted CN45 gag epitope demonstrated a 
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substantial population of antigen-specific CD45+ MHCII- CD8+ cells expressed biomarkers of 
anti-viral CD8 effector T cells, IFNγ and/or Granzyme B (Fig. 2d and 2e). When immunised or 
naive mice were challenged intra-vaginally four weeks post ID or MA immunisation with 
5x108 plaque forming units (pfu) recombinant VV expressing the cognate HIV-1 gag CN54 
antigen (Fig 2f) we found a significant decrease in viral titres within the FRT of the 
immunised mice when cross compared with the naive group (P<0.001, one-way ANOVA) on 
day 6 post challenge (Fig 2g). These data indicate that immunisation through the skin has 
the capacity to induce a robust and protective CD8+ T cell response in the FRT.  
Biodistributed Ad5 is insufficient to prime FRT CD8 T cells 
To determine the mechanism by which antigen-specific CD8+ T cells seed the FRT following 
skin immunisation, we first enumerated Ad5 vector genomes by quantitative PCR in several 
tissues at an early time point after immunisation to address if virus bio-distributed from the 
skin to the FRT and if that was sufficient to locally prime CD8+T cells within the female 
reproductive tissue. At 24 h post MA immunisation with Ad-CN54gag (1x109 vp), a low but 
reproducible copy number of Ad genomes were detected in FRT tissue, liver, lung and 
spleen (Fig. 3a).  While the genome content in these tissues was significantly lower than that 
detected in the skin (p<0.001) or skin draining LNs (p<0.05) by one-way ANOVA, it was 
consistently and markedly greater than the Ad genome content (per 100 ng of DNA) in blood 
(Fig. 3a and 3b) indicating that virus bio-distributed from the skin to peripheral non-lymphoid 
tissues. The capacity of this low dose of bio-distributed virus particles to prime CD8+T cells 
locally in the vaginal mucosa was assessed by intra-vaginal injection of naive mice with 
3.5x102 vp Ad-CN54 gag that was equivalent to the Ad5 genome content detected in the FRT 
after skin immunisation. Tracking by tetramer did not reveal Db/CN54 gag Tet+ CD8+ T cells 
in the iliac LNs (Fig. 3c) or FRT at day 7 or 14 after intra-vaginal immunisation with 3.5x102 
vp Ad CN54 gag (Fig. 3d, Supplementary Fig. 3). In contrast, the skin-priming dose (1x109 
vp) when injected intra-vaginally elicited a high frequency of CD11ahiDb/CN54 gag Tet+ CD8+ 
T cells in the FRT (Fig. 3d, Supplementary Fig 3a,b) that was not statistically different from 
	   8	  
that elicited in the FRT after skin immunisation by MA (p=0.23 by one-way ANOVA). 
Therefore, the Ad-CN54 gag virus dose bio-distributed from skin to the FRT was below the 
threshold required to prime antigen-specific CD8+T cells locally in the vagina and iliac LNs.   
FRT CD8 T cell recruitment requires CXCR3 independent of Ag 
We next addressed if effector CD8+ T cells from the systemic compartment gained the ability 
to migrate to the FRT after skin immunisation and if specific cues drove their migration. To 
that end, Db/CN54 gag Tet+ CD8+ T cells in blood and FRT at day 7 after skin immunisation 
were screened by flow cytometry against a chemokine receptor and integrin panel of 
acknowledged homing molecules. Of note, chemokine receptors associated with 
inflammation (CCR1, CXCR6) were expressed at high frequency (Supplementary Fig. 4) with 
CXCR3 universally expressed (> 98%) on Db/CN54 gag Tet+ CD8+ T cells in the blood and 
FRT at day 14 after skin (ID or MA) immunisation (Fig. 4a). These observations were not 
restricted to the genital mucosal tissues. High frequency activated Db/CN54 gag Tet+ CD8+ T 
cells were detected in the lung after ID/ MA immunisation (Supplementary Fig. 5a) and the 
majority expressed CXCR3 (Supplementary Fig 5b). Likewise, the CD8+ Tet negative 
Db/CN54gag308-318 population from the FRT of immunised but not naive mice was enriched for 
CXCR3+ expression (p<0.05 by one-way ANOVA) (Supplementary Fig 6). This may indicate 
CXCR3+CD8 T cell effectors that are primed against additional TCR specificities including the 
vector and the gag protein are recruited to the FRT.  
To test if CXCR3 expression was necessary to permit spleen derived CD8+ T cell effectors to 
migrate to the FRT after immunisation we used a transfer system of congenic Rag-/- CD45.1 
T cell receptor transgenic OT-I CD8+ T cells (CD45.1 OT-I) specific for the ovalbumin (OVA) 
peptide 257-264 to track migration in groups of wild type (WT) recipients immunised in the 
skin (1x109 vp Ad-OVA) or by intra-vaginal injection with the bio-distributed virus dose 
(3.5x102 vp Ad-OVA / Ad-CN54 gag). To generate effector CD8+ T cells, 2x105 naïve CD45.1 
OT-I cells were transferred into WT mice. Six days after Ad-OVA skin immunisation some 
were treated with anti-CXCR3 Ab while others were treated with isotype control Ab. On day 
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7, effector CD45.1 OT-I cells (2x106) isolated from anti-CXCR3 Ab treated or isotype control 
Ab treated mice were transferred into secondary recipients (treated with anti-CXCR3 Ab or 
isotype control Ab), which had been immunised by MA or by intra-vaginal injection 3.5 days 
earlier (Fig. 4b). Flow cytometry confirmed surface CXCR3 was blocked on cells from anti-
CXCR3 treated mice (Supplementary Fig. 7). As a control for antigen specificity, some 
secondary recipients were intra-vaginally injected with Ad-CN54 gag or PBS 3.5 days prior to 
effector OT-I cells transfer (Fig. 4b). After 1.5 days, CD45.1 OT-I cells were quantified from 
recipient tissues. The number of CD45.1 OT-I effectors recovered from the blood and spleen 
was similar in naive and immunised mice, irrespective if the transferred cells expressed 
CXCR3 or were blocked for CXCR3 (Fig. 4c and 4d). However, as expected transferred 
CXCR3+CD45.1 OT-I cells were excluded from the FRT of naive recipients. In contrast, a 
significant number of transferred CXCR3+CD45.1 OT-I cells were recovered from the FRT, 
both of mice immunised with Ad-OVA in the skin and from recipients immunised intra-
vaginally with the low virus dose that bio-distributed from the skin to FRT (Fig. 4e). Moreover, 
migration of transferred CD45.1 OT-I cells to the FRT that was independent of the antigen 
encoded by the intra-vaginally injected Ad vector, but was absolutely dependant on CXCR3 
expression of the transferred cells, as treatment with anti-CXCR3 Ab inhibited CD45.1 OT-I 
cells homing to the FRT (Fig. 4e). These data suggest that the low level of virus that bio-
distributes from skin to the FRT is sufficient to recruit systemic CD8+ T cell effectors to the 
FRT and that migration was dependant on expressed CXCR3 but independent of antigen-
specificity. 
Skin immunisation upregulates CXCL9 on FRT myeloid cells 
To test the hypothesis that innate cells in peripheral non-lymphoid tissues remote from the 
site of immunisation played a role in CD8+ T cell recruitment to that tissue we examined 
myeloid populations for expression of CXCL9, an effector chemokine and cognate ligand of 
CXCR3 35 in the FRT after skin immunisation. We found a significant increase in FRT 
CD45+CD11b+ cells that expressed CXCL9 from skin immunised mice, both ID and MA when 
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compared with naive (Fig. 5a). Likewise in the lung, there was a marked increase in 
CXCR9+CD45+CD11b+ cells after skin immunisation (Supplementary Fig. 8). Deeper 
phenotypic analysis of CD11b+ cells revealed a distinct and significant increase in the 
frequency of cells that expressed CXCL9 within the CD45+Ly6Chi CD11b+ MHCII- CD11c- 
population, hereafter referred to as ‘Ly6Chi monocytes’ (Fig. 5b) and within the CD45+CD11b+ 
MHCII+ CD11c+ population referred to as ‘dendritic cells’ (Fig. 5c) in the FRT at day 7 and for 
at least 14 days post skin immunisation (Supplementary Fig 9a and 9b). Collectively, the 
data suggest that skin immunisation with an Ad vectored vaccine engenders expression of 
CXCL9 by CD11b+ subsets in peripheral non-lymphoid barrier tissues. 
FRT monocytes and ILC1 accumulate after skin immunisation 
Our observation that monocytes within the FRT expressed CXCL9, an IFNγ-inducible 
chemokine in the context of skin immunisation, raised the possibility that production of 
CXCL9 may be enforced by innate lymphoid cells such as classical natural killer cells 
reported capable of producing IFNγ 36,37. There are precedents to support this idea as 
adenovirus is a strong inducer of NK cell activation 28,38,39 and NK cell-derived IFNγ can prime 
monocyte functions 40. To that end, we assessed the kinetics of monocyte and ‘NK-like’ ILC1 
accumulation in the blood and FRT after skin (MA) immunisation with Ad-CN54 gag. As 
expected, NK-like ILC1 (defined as CD3- NK1.1+ and referred to hereafter as ILC1) and 
Ly6Chi monocytes rapidly accumulated in the blood within 3 h of skin immunisation peaked 
after 6 h and returned to base-line at 24 h, with a second influx (increase) in blood Ly6Chi 
monocytes at 48 h after immunisation (Fig. 6a, Supplementary Fig 10).  Contrastingly, a peak 
in frequency of ILC1 within the FRT was evident at 24 h that represented a 2.2-fold increase 
compared to naive mice (Fig. 6b), with CD69 (an early activation and tissue retention marker) 
highly expressed on the majority of ILC1 (Fig. 6b). A significant influx of Ly6Chi monocytes 
within the FRT was not apparent until 72 h post skin immunisation (Fig. 6b) but remained 
elevated for at least 14 days (Supplementary Fig. 11). Thus, after skin immunisation with an 
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Ad5 vectored vaccine there is a marked accumulation of CD69+ ILC1 in the FRT that have 
the potential to engage in cross talk with recruited Ly6Chi monocytes.  
 
Biodistributed Ad5 sufficient to recruit monocytes and ILC1 
Next, we addressed if bio-distribution of virus from the skin to peripheral tissues in the 
context of skin immunisation was sufficient to induce the observed increase in ILC1 and 
Ly6Chi monocytes within the FRT. Mice were administered Ad-CN54 gag, either 1x109 vp by 
MA to the skin or 3.5 x 102 vp (equivalent to the bio-distributed virus dose) by injection into 
the wall of the vagina (Fig. 7a). At 24 h post virus immunisation a substantial increase in 
frequency and total number of ILC1 was detected in the FRT of immunised relative to naive 
mice (p<0.001 and p<0.01 respectively by one-way ANOVA) that was not significantly 
different if the low (bio-distributed equivalent) virus dose was injected intra-vaginally as 
opposed to skin priming by MA (Fig. 7c, Supplementary Fig.7). Likewise, at 72 h post 
immunisation, the low virus dose injected intra-vaginally led to a significant increase in 
frequency and total number of Ly6Chi monocytes within the FRT relative to naïve mice 
(p<0.01, Fig. 7e) that was not significantly different (p>0.05) from mice immunised by MA in 
the skin (Fig. 7e, Supplementary Fig. 12) analysed by one-way ANOVA. Of note, the stress 
response from injection into the vaginal wall (with PBS) did not account for the increase in 
FRT ILC1 or Ly6Chi monocytes associated with the intra-vaginally injected low virus dose 
(Fig. 7e, Supplementary Fig. 12). These data strongly suggest that virus bio-distributed from 
skin to the FRT after skin immunisation is sufficient to modify the peripheral tissue 
environment such that this resulted in recruitment of ILC1 and inflammatory monocytes to the 
FRT tissue. 
CD8 T cell recruitment to FRT requires ILC1 intrinsic IFNγ  
To better understand the role of innate lymphoid-like cells in recruitment of CD8+ T cells to 
the FRT we treated mice with an anti-NK1.1 depleting antibody one day prior to and at three-
day intervals following skin immunisation with Ad-CN54 gag (Fig. 8a). This treatment resulted 
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in nearly complete ablation of the CD45+ CD3- ILC1 population in the FRT and CD3-CD19- 
ILC1 cells in the blood (Supplementary Fig. 13). Strikingly, we observed that anti-NK1.1 
antibody treatment was associated with a significant decrease in the frequency of Db/CN54 
gag Tet+ CD8+ T cells in the FRT when compared with the control treated group (p<0.01, by 
one-way ANOVA, Fig. 8c). Conversely, there was no such substantial decrease in Db/CN54 
gag Tet+ CD8+ T cells in the blood after anti-NK1.1 antibody treatment Fig. 8b). Moreover, 
expression of CXCR3+ remained unchanged on Db/CN54 gag Tet+ CD8+ T cells in the blood 
or FRT after anti-NK1.1 antibody treatment (Fig. 8d and 8e). Thus CD8+ T cell recruitment to 
the FRT after skin immunisation showed a strong dependence on ILC1 within the FRT 
despite this tissue not being the site of immunisation.  
Since accumulation of ILC1 preceded peak expansion of inflammatory monocytes in the FRT 
(Fig. 6b) and expression of CXCR3 was essential for CD8+ T cell recruitment (Fig. 4) we 
reasoned that ILC1 might be crucial to program CXCL9+ by Ly6Chi monocytes and enable 
CXCR3 driven CD8+ T cell recruitment to the FRT. Treatment with anti-NK1.1 significantly 
decreased the frequency of CXCL9+ Ly6Chi monocytes in the FRT at 72 h after skin 
immunisation compared with immunised control treated mice (Fig. 8f and 8g) consistent with 
the hypothesis that innate lymphoid cells play a key role in priming CXCL9 expression by 
FRT inflammatory monocytes in the context of skin immunisation. That IFNγ might be 
essential in priming CXCL9 by Ly6Chi monocytes in this system was addressed by injecting 
wild type and RAG-1-deficient (Rag1-/-) mice that lack conventional T cells, NKT cells and B 
cells 41 with anti-IFNγ on the day prior to and daily after skin immunisation with Ad-CN54 gag 
(Fig. 8h). Anti-IFNγ significantly impaired the increase in frequency of CXCL9+ Ly6Chi 
monocytes within the FRT associated with skin immunisation (Fig. 8i and 8j) both in wild type 
and Rag1-/- mice, suggesting an innate cell intrinsic IFNγ source was necessary to induce 
CXCL9. Consistent with that concept, the CXCL9 response of FRT Ly6Chi monocytes 
following skin immunisation with Ad-CN54 gag was unaltered in Rag2-/-γc-deficient (Rag2-/- X 
IL-2Rγcnull) mice (that lack innate lymphoid cells) when cross-compared with the response of 
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naïve Rag2-/-γc-deficient and in contrast to wild type immunised mice (Fig. 8j). Taken 
together, these data are consistent with the conclusion that innate lymphoid cell intrinsic 
IFNγ  in the local environment of the FRT is necessary and sufficient to promote CXCL9 
production by Ly6Chi monocytes and licence recruitment of CXCR3+ CD8+ T cells to the FRT 
following skin immunisation.  
 
Discussion 
Innate lymphoid cells, emphasised by the group 1 subset are recognised to play an important 
role in protecting the epithelial barriers against intracellular infection 37,42,43. This has been 
attributed to their capacity to rapidly produce IFNγ in response to local pro-inflammatory 
cytokines 40,44. In this way, they directly restrict early pathogen replication at the initial site of 
infection 42-46. Until now is has been unappreciated that signals communicated by innate 
lymphoid cells can also permit CD8+ T cells primed after skin immunisation (or infection) to 
seed distal epithelial tissues despite these tissues not being the target of infection. In this 
way, innate lymphoid cells can indirectly provide protection at the epithelia from secondary 
pathogen spread or future infection via promoting T cell recruitment. Here we elucidate how 
this occurs using an Ad vaccine vector. After skin immunisation, vaccine vector bio-
distributes at very low levels to peripheral tissues including the FRT that is sufficient to 
mobilise primed CXCR3 expressing CD8+ T cells to that tissue. Our study revealed that an 
innate lymphoid cell population in the local tissue could orchestrate CXCR3-dependent 
recruitment by responding rapidly and prime CXCL9 production by Ly6Chi monocytes via cell 
intrinsic IFNγ.  Together, our data suggest a general mechanism whereby ILC1 can regulate 
antigen-primed CXCR3+ CD8+ T cells to barrier tissues that are not the target site of 
immunisation. Importantly, we demonstrate this mechanism provides protection from VV 
pathogen challenge in the FRT.  
It is currently understood that exposure of the vaginal mucosa to topically applied 
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chemokine’s or to microbicides that create non-specific inflammation permits recruitment of 
systemically primed CD8+ T cells to the FRT 26,47. This implies that signals derived from the 
microenvironment of epithelial barrier tissues can ‘pull’ circulating effector CD8+ T cells into 
the tissue and establish tissue residence 26. Thus, neither direct immunisation nor on-going 
infection of the FRT are strictly essential for the establishment of memory CD8+ T cells 
bearing hallmarks of CD8+ TRM cells in the tissue 17,25,26,47. Our data advance this concept by 
demonstrating that immunisation through the skin (and also by the IM route) with an Ad5 
vaccine vector instructs peripheral tissues including the FRT and lung to recruit systemically 
generated CD8+ T cell effectors. In agreement with Iwasaki and colleagues 48 CD8+ T cell 
expressed CXCR3 was absolutely essential for CD8+ T cell recruitment to the FRT. 
Nonetheless, the mechanism conditioning the FRT (and lung) to express the requisite 
cognate chemokine ligand differ, likely dictated by the pathogen/vaccine and site of 
pathogen/vaccine exposure. These different contexts might explain a seeming paradox that 
CD4+ T cell induced IFNγ is essential for CXCL9 driven CD8+ T effector extravasation to the 
FRT and lung in respect of local HSV-2 and influenza virus infection respectively 48,49. In 
contrast, our study showed NK1.1+ ILC1 intrinsic IFNγ, but not CD4+ T cell induced IFNγ, is 
necessary and sufficient to drive Ly6Chi monocyte expressed CXCL9. This is essential for 
NK1.1 dependent CD8+ effector T recruitment to the FRT where the initial Ad5 virus vector 
exposure is in the skin. Thus NK1.1+ ILC1 can provide an IFNγ signalling module and licence 
CXCL9 production that resembles an effector function provided by CD4+ Th1 cells 36,37,50 but 
differs from CD4+ Th1 cells by the absence of TCR specificity in initiation of CXCL9 driven 
CD8+ T effector extravasation. The licensing properties of ILC1 reported herein are 
consistent with the ability of activated NK cells to cluster with CD11b+ cells 51,52 and Ly6Chi 
monocytes 44 during infection and prime their activation via IFNγ 44,53. Therefore, Ly6Chi 
monocytes and CD11b+ DCs are likely complementary as producers of a CXCL9 
microenvironment necessary for recruitment of systemically primed CD8+ effector T cells to 
epithelial barrier tissues.  Our findings bare direct relevance to optimising delivery of 
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vaccines where local immune surveillance by recruited CD8+ T cells plays a critical role in 
protection at the epithelial barrier 3,54. In contrast, vaccines that provide antibody-based 
protection at the cervico-vaginal epithelia, exemplified by the IM administered prophylactic 
HPV sub-unit vaccine, have been proposed to work by a different mechanism, transudation 
or exudation of serum IgG as opposed to providing signals to recruit antibody secreting cells 
to the epithelia 55. 
An outstanding question remains, how do ILC1 within distant epithelial barrier tissues 
proliferate and undergo activation that conditions the FTR to recruit CD8+ T effectors in 
response to skin immunisation? Immune connectivity across distant epithelial barrier tissues 
has been revealed previously following skin vaccination 17,25,26,47,56. This may reflect the 
action of type I IFN 56 or other innate mediators responding at the site of immunisation 57, 
acting systemically that may be essential for ILC1 activation. Unlike MVA 56 or adjuvanted 
vaccines 57, rAd5 used in this study, is a weak inducer of serum IFNα 28,58. Equally, type I IFN 
dependent activation of NK cells is not a property of rAd5 58, thus other mechanisms must 
operate. Intriguingly, our study found a low but consistent copy number of vaccine vector 
genomes in peripheral non-lymphoid tissues (including the FRT) after skin immunisation, 
consistent with previous reports 59-61. The bio-distributed Ad5 vector dose in this study had 
the capacity to recruit populations of ILC1, Ly6Chi monocytes and CXCR3hi CD8+ T effector 
cells to the FRT after intravaginal injection of naive mice. This leads us to speculate that low 
levels of virus vector may bypass subcapsular sinus macrophages in skin draining LN after 
immunisation and disseminate systemically 62. There is a precedence that blood monocytes 
can rapidly interact with Ad5 63 and are highly suited to hijack and transport virus or virus 
genome via the blood circulation to distal tissues 64,65. Equally, monocytes are acknowledged 
to enter extravascular tissues and replenish resident monocyte-derived cells under steady-
state conditions 66,67. This might be one mechanism by which cross talk between monocytes 
carrying virus / vector genome and tissue resident ILC initiate a feedback loop to recruit 
waves of monocytes and ILC1 that may condition the FTR in the context of skin 
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immunisation. Although our study with Ad5 vectored vaccines emphasised local activation of 
innate NK 1.1+ cells and their role in orchestrating recruitment of CD8+ T effector and CD8+ 
TRM cells to the FRT after skin immunisation, our findings do not preclude if this response 
state of NK1.1+ cells might also be dictated in part by cytokines acting systemically from the 
site of immunisation 68. Additional studies with other vaccine vectors and forms of 
immunogens will be important. 
In conclusion, we have defined a mechanism whereby skin vaccination  induces low-level 
inflammation in the FRT that is sufficient to promote CD8+ T-cell recruitment through a 
CXCL9 dependent mechanism licensed by ILC1 cells. These data may have important 
implications for vaccine designs against pathogens transmitted across epithelial barrier 
tissues and highlight the attributes of skin as a delivery site to stimulate prophylactic and 
therapeutic immunity against vaginally acquired infections.  
 
Methods  
Recombinant Adenovirus vaccines  
Replication–deficient, E1, E3 deleted adenovirus type 5 (Ad5) vaccine vectors were 
propagated in low passage human embryo kidney 293 (293AD) cells (Cambridge 
Biosciences) at a multiplicity of infection of 25 virus particles per cell (as titrated by the DNA 
Pico-Green assay, Invitrogen) and then purified by the Native Antigen Company.  Viruses 
were stored at −80°C until use.  rAd5-HIV-1 CN54 gag encodes a codon optimized 
synthetic HIV-1 CN54 gag gene reported previously 27.  Ad5-OVA encodes a non-secreted 
chicken ovalbumin gene, constructed by Dr M. Zenke’s laboratory (Aachen University, 
Aachen, Germany)  27. Virus particle titres were determined by the DNA Pico-Green assay 
(Invitrogen).  
Recombinant Vaccinia virus HIV-1 CN54 gag 
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A codon optimised synthetic HIV-1 CN54 gag gene sequence (Supplementary Fig 14) was 
amplified using HIV-1 CN54 gag primers (Supplementary Table 1) using high fidelity PCR by 
Invitrogen pFx polymerase and inserted into a plasmid containing vaccinia virus thymidine 
kinase flanking arms (pVACV-TK). Recombinant plasmid was sequenced to confirm insertion 
and sequence fidelity. Sub-confluent BHK cells (2x106 cells) were transfected with 2 µg of 
pVACV-TK-CN54gag using Lipofectamine and Plus Reagent (Invitrogen) and co-infected 
with parental VACV::GyrB-PKR at an MOI of 0.05 pfu/cell. At 30 h post-infection, cells were 
scraped and virus released by three rounds of freeze-thaw treatment followed by sonication. 
RK13 cells pre-treated with coumermycin A1 (100 ng/ml) for 16 h were infected with dilutions 
of the in vitro recombined virus extract and overlaid with media containing coumermycin.  30 
h post-infection plaques were isolated and amplified under selection with cumeromycin in 
RK13 cells. Amplified virus was purified by centrifugation through 36% sucrose.  Virus was 
maintained under selection at all times and sequences were confirmed by Arizona State 
University core sequencing laboratory.  
Fabrication of microneedle arrays (MA) 
Dissolvable microneedles (1500 µm in length, 670 µm in base diameter and 44 per array) 
were fabricated by a centrifugation casting method (at 1780 x g for 1 min) using an inverted 
cone shaped silicone template. Vaccine vectors were formulated in the matrix of the needle 
tips at a 1:1 ratio with sodium carboxyl methylcellulose (8% wt/vol Na-CMC) and sucrose 
(30% wt/vol). A second layered matrix (12% Na-CMC, 4.8% lactose) created the needle shaft 
and a pre-made membrane (8% Na-CMC, 0.8% lactose) formed the needle base. After air 
drying (24 h at room temperature) the MAs were carefully removed from the template and 
stored in a desiccator at room temperature. 
Mice 
Female mice at 7-8 weeks of age were used in this study. C57BL/6 mice were purchased 
from Envigo. Rag-/- OT-I mice on a CD45.1 background (B6.SJL CD45.1) were from The 
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Francis Crick Institute (London) and Rag1-/- and Rag2-/-γcnull mice were bred at King’s College 
London. The minimum numbers of mice required to obtain statistically significant and reliable 
results were used. The number of animals within each study arm is denoted within the 
appropriate figure legends.  
Ethics statement 
All animal husbandry and experimentation was approved by King’s College London ethics 
committee and performed under a project license granted by the United Kingdom Home 
Office. 
Depo-Provera synchronization 
All mice in this study received medroxyprogesterone acetate, Depo-Provera (Depo®, Pfizer) 
at a dose of 3mg by s.c. injection 5 days before each experiment.	   
Immunisation models 
Mice received either 1x109 vp (or where indicated 1x107 vp) of rAd5 vaccine vector either by 
MA administration, where MAs were applied manually with gentle pressure (5 min) to the 
shaved dorsal surface of the ear or back skin (as indicated) or by ID or IM injection.. In some 
experiments, mice received the designated dose (or a lower dose, where indicated) of rAd5 
vaccine vector by injection directly into the vaginal wall.  
Adoptive transfer 
Naïve donor antigen-specific CD8+ T cells were isolated from the spleens of CD45.1+ 
transgenic OT-I mice and magnetically purified (> 96 %) using a CD8
 
T cell isolation kit 
(Stemcell Technologies). For effector cell generation, 2x105 naive CD45.1 OT-I CD8+ donor 
T cells were adoptively transferred into recipient B6 mice. The next day, recipients were 
immunised ID with 1x109 vp of rAd5-OVA. Some recipient mice were injected i.p with 
blocking antibody against CXCR3 (200 ug, clone:	  CXCR3-173, 2BScientific) at day 6 post-
immunisation. FACS analysis confirmed CXCR3 depletion (> 99.5 %). Effector OT-I cells 
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(either CXCR3 depleted or not) were isolated from the spleen at 7 days post immunisation. 
Single cell suspensions were purified using the MagniSortTM mouse CD45.1 positive 
selection kit and then 2x106 cells were transferred i.v into naive hosts or into secondary 
recipients immunised 3.5 days previous to cell transfer with either rAd5-OVA (by skin MA or 
by intravaginal immunisation) or with rAd5-HIV-1 CN54 gag or with PBS by intravaginal 
immunisation (as indicated). On the day of cell transfer, recipients of CXCR3 blocked CD45.1 
OT-I also received an i.p injection of 200 ug anti-CXCR3 antibody (clone:	   CXCR3-173, 
2BScientific). After one and a half days, the numbers of CD45.1 OT-I cells harvested from 
the blood, spleen and FRT of naive and secondary recipients were analysed by flow 
cytometry. 
Isolation of cells from tissues  
At various time points, single cell suspensions were prepared from blood, spleen and LNs 
and re-suspended in complete RPMI [RPMI medium 1640 supplemented with 100 U/mL 
penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine (Invitrogen), and 10% heat inactivated 
FBS (Biosera).. Liver, lung and FRT (where indicated) were harvested following perfusion. 
Single cell suspensions from the FRT and lung were obtained by enzymatic digestion for 30 
min at 37°C using 1 mg/mL Collagenase D (RocheTM) and 0.02 mg/mL DNase I from bovine 
pancreas (RocheTM).  
Flow cytometry   
The following antibodies (including clone and catalogue number) were purchased from BD 
Bio-sciences: purified anti-FcRII/III mAb (CD16/32, 2.4G2), anti-CD8 (53–6.7), anti-CD4 
(RM4-5), anti-CD11b (M1/70), anti-CD3 (145-2C11), anti-MHC class II (2G9), anti-Gr-1 
(RB6-8C5), anti-CD45R/B220 (RA3-6B2), anti-CD25 (7D4), anti-CD4 (GK1.5), anti-CD115 
(AFS98), anti-NKp46 (29A1.4), anti-CD49b (DX5), anti-CCR1 (S15040E), anti-CCR5 (HM-
CCR5), anti-CCR6 (29-2L17), anti-CCR7 (4B12), anti-CCR9 (9B1), anti-CCR10 (6588-5), 
anti-CXCR3 (CXCR3-173), anti-CXCR6 (SA051D1), anti-CXCL9 (MIG-2F5.5), anti-CD11c 
(HL3) and anti-α4β7 (DATK32). In addition, anti-IFNγ (XMG1.2), anti-Granzyme B (NGZB), 
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anti-Ly6C (HK1.4), anti-CD69 (H1.2F3) and anti-CD11a (M17/4) were obtained from 
eBioscience. Anti-NKp46 (29A1.4), anti-NK1.1 (PK136), anti-CD45 (30F-11), anti-CD8 (53–
6.7), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD11c (N418) and anti-MHCII 
(M5/114.15.2) were acquired from Biolegend. Dilutions at which antibodies were used are 
shown in Supplementary Table 2. Tetramers to the immunodominant H-2Db restricted HIV-1 
CN54 gag 308-318 epitope (Db/CN54gag) were kindly synthesised by the NIH Tetramer core 
facility (Emory University, USA).  Cells were stained with Db/CN54gag tetramer (15 min) at 
room temperature, followed by addition of cell surface antibodies (20 min) and then re-
washed. For intracellular cytokine staining, 1 × 106 cells per mL were incubated 6 h at 37 °C 
with anti-CD28 (2 µg/mL) either alone (unstimulated control) or with peptide HIV-1 CN54 gag 
308–319 (2 µg/mL).  Brefeldin A (10 µg/mL) (Sigma-Aldrich) was added for the last 5 h of 
culture. After washing, cells were incubated with anti-FcγRII/III (10 min), followed by staining 
with Db/CN54gag tetramer (15 min) prior to incubation with antibodies to cell surface 
markers (20 min). Cells were fixed and permeabilized with the BD Cytofix/Cytoperm Kit 
according to the manufacturers’ instructions and then stained simultaneously with the 
Db/CN54gag tetramer, anti-IFNγ and anti-Granzyme B antibodies (20 min).  Samples were 
acquired using a BD FACSCanto II or BD SORP LSRFortessa™ flow cytometer and 
analysed using FlowJo software version 9.7.5 (Tree Star) for Mac. Gating strategies to track 
Db/CN54gag Tet+ CD8+ T cells in blood, LN, FRT, lung and spleen are shown in 
Supplementary Fig. 15. Gating strategy to define (i) Ly6Chi monocytes, DCs and NK1.1+ 
(ILC1) cells in blood and FRT; (ii) to examine CXCL9 expression by Ly6Chi monocytes and 
DCs in blood, FRT and lung and (iii) to examine CD45.1+ OT-1 cells following adoptive 
transfer in tissues are shown in Supplementary Fig 16. 
 
Quantitative real-time PCR  for adenovirus copy number 
Quantitation of Ad5 copy number in tissues after MA immunisation was conducted by using a 
real-time TaqMan RT-PCR system. DNA was purified from collected tissues using a Gene 
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EluteTM Mammalian Genomic DNA kit (SIGMA-ALDRICH), according to the manufacturer’s 
instructions. The purified DNA was mixed with; TaqMan PreAmp Master Mix (2x) (Applied 
Biosystem), the primer pair (Supplementary Table 1) and TaqMan Probe	   FAM-
taccagaacgaccacagca-MGB (total volume per reaction: 10 ul). The mixture was amplified in 
an automated fluorometer, QuantStudio5 (Applied Biosystem) under the following conditions: 
40 cycles of 95°C for 15 s and 60°C for 60 s. rAd5-HIV-1 CN54 gag was used as a standard.  
Virus challenge and plaque assay 
Groups of mice were challenged by depositing 5x107 vp of rVV-CN54gag into the vaginal 
cavity and monitored for 6 days. FRT tissues were harvested at 6 days post rVV-CN54gag 
challenge and homogenised by enzymatic digestion for 30 min at 37°C using 1 mg/ml 
Collagenase D (RocheTM). The supernatants were serially diluted (10-2 to 10-7) in Dulbecco’s 
modified Eagle’s medium (DMEM) and added onto BSC-40 cell monolayers for 1 h at 37°C. 
Cells were then cultured in complete DMEM containing 5% fetal calf serum (FCS) and 
containing coumermycin A1 (100 ng/ml) for 48 h before fixation an de-staining with 0.1% 
crystal violet solution for counting viral pfu. 
In vivo killing assay 
Naive syngeneic splenocytes were labeled with CFSE at 5 μM (CFSEhi) or 0.5 μM (CFSElo), 
pulsed with or without peptide to the immunodominant Db restricted HIV-1 CN54 gag epitope 
(5 ug/ml), then 1x106 cells (mixed at a 1:1 ratio) injected using a Hamilton syringe with 30G 
needle into the vaginal wall of immunised or naive control mice and harvested after 24 h to 
measure in vivo cytolysis of target cells by the loss of the CFSEhi peptide-pulsed population 
relative to the control CFSElo population by flow cytometry. 
 
In vivo antibody dependent cell depletion or neutralisation 
For depletion of NK1.1 expressing innate cells, mice were injected 200 µg of purified 
monoclonal NK1.1 antibody (PK136, BioXcell) i.p. 24 h before immunisation, followed by 
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injections on day 0, 3, 6, 9 and 12. For IFNγ neutralisation, mice were injected i.p with 
purified anti-IFNγ antibody (XMG1.2, BioXcell) 24 h before and daily after immunisation.  
Control mice received their corresponding isotype Ab. 
Statistical analysis 
Results were analysed with GraphPad PRISMTM version 6.0 (San Diego, Ca, USA). Bars in 
figures show the mean ± SEM. Comparisons between groups were performed using a one-
way ANOVA in conjunction with Bonferroni post analyses test. Probability values are 
expressed as following: ***p<0.001, **p<0.01 and *p<0.05.	  	  
Data Availability 
All relevant data are available from the authors upon reasonable request. A reporting 
summary for this Article is available as a Supplementary Information file. The source data 
underlying all reported averages in graphs underlying Figs 1c,1d,1g, 2c, 2g, 2e, 3a-d, 4a, 4c-
e, 5a-c, 6a-b, 7b-e, 8b-e and 8j and Supplementary Figs 1, 2, 6, 8, 9 and 11  are provided as 
a Source Data file. 
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Figures 
	   
Figure 1. Skin immunisation irrespective of anatomic site recruits CD8+ T cells to the 
FRT (a) Experimental design. (b, c, d) Flow cytometry plots and graphs showing frequencies 
of CD8+ Db/CN54gag tet+ cells in blood (day 10) and indicated tissues (spleen, inguinal LN 
and FRT) on day 14 after ID or MA (back skin) immunisation with Ad-CN54gag. Data are 
from four independent experiments (n=7-18 mice per group). (e) Experimental design. Mice 
were immunised by MA either to the dorsal surface of the ear or to back skin or ID (f, g) Flow 
cytometry plots and graph showing frequencies of CD8+ Db/CN54gag tetramer+ cells in FRT 
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(day 14). Data are representative of two independent experiments (n=3-4 mice /group). (d,g) 
p>0.05 (ns) by one-way ANOVA, error bars show s.e.m. 
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Figure 2. FRT CD8+ T cells induced by skin immunisation are cytolytic and protect 
against vaginal virus challenge. (a) Experimental design. Syngeneic donor spleen cells 
pulsed with peptide to the immunodominant Db/HIV-1 CN54 gag epitope (CFSEhigh) and 
control non-pulsed (CFSElow) syngeneic donor spleen cells (106 at 1:1 ratio) were injected 
into the vaginal mucosa of Depo-Provera treated, Ad-CN54 gag immunised /naive mice. 
After 18 h, CFSE-labelled donor cells isolated from the vaginal mucosa analysed by flow 
cytometry. (b) Representative flow cytometry CFSE profiles. (c) Percentage specific lysis of 
HIV-1 CN54 gag peptide-coated donor cells in vagina of recipient mice.  Data are from 2 
independent experiments (n=6-9 mice /group), **p <0.01 by one-way ANOVA, error bars 
show s.e.m. (d,e) Representative flow cytometry profiles and summary graph of IFNγ and/or 
Granzyme B expressed by CD8+ T cells isolated from FRT tissue 14 days after Ad CN54 gag 
skin immunisation and stimulated in vitro with peptide specific to the immunodominant 
Db/CN54 gag epitope.  Data represent n= 5 mice / group. (f) Experimental design for testing 
host protection from vaginal infection with rVV-CN54gag (107 pfu) conferred by skin 
immunisation (ID or MA) with Ad-CN54gag. (g) Virus (VV) titres in the vaginal mucosa were 
measured by plaque assay on day 6 post-virus challenge. Data are representative of two 
independent experiments with a total of 4-12 mice per group. ***p <0.001 by one-way 
ANOVA, error bars show s.e.m. 
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Figure 3. Bio-distributed rAd5 vaccine vector does not prime CD8+ T cells in FRT or 
iliac LNs. (a) Quantification of Ad vector genomes by qPCR sequestered in indicated organs 
at 24 h post-MA immunisation with Ad-CN54 gag (1 x 109 vp). (b) Ad vector genomes 
quantified in whole blood at 2 and 24 h post skin (MA) immunisation with Ad-CN54 gag (1 x 
109 vp) (a,b). Data are from 2 independent experiments (n= 4-10 per group).  (c,d) 
Frequencies Db/CN54 gag tet + CD8+T cells in FRT tissue and iliac LNs after skin (MA) or 
intra-vaginal immunisation with Ad-CN54 (1 x 109 vp) or with the vector dose (3.5 x 102 vp) 
equivalent to the copy number detected by qPCR in FRT after skin immunisation. Data (n=4-
9 per group) are from three independent experiments. P>0.05 (ns), **p<0.01, ***p<0.001 by 
one-way ANOVA, error bars show s.e.m. 
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Figure 4. CXCR3 is essential for recruitment of CD8+ T cells to FRT, independent of 
antigen-specificity. (a) Representative flow cytometry profiles and graphs showing 
frequency of CXCR3+ Db/CN54 gag tet+ cells in blood (upper panels) and FRT (lower panels) 
14 days after skin immunisation; ID (blue histograms) or MA (red histograms); grey-filled 
histograms represent unstained control, all gated from a CD45+CD4-MHCII-CD8+ population. 
Bar graphs summarise data from two independent experiments (n=6 for experimental 
groups). (b) Experimental design. Congenic CD45.1 OT-I cells (2×105) were transferred into 
WT mice. Five days after Ad-OVA skin immunisation some were treated with anti-CXCR3 
Ab.  On day 7, effector OT-I cells (2x106) isolated from these mice were transferred into 
secondary hosts (some treated with anti-CXCR3 Ab) infected with either Ad-OVA via MA or 
intra-vaginal injection 3.5 days earlier. Some secondary recipients were intra-vaginally 
injected with Ad-CN54 gag or PBS 3.5 days prior to effector OT-I cells transfer. (c,d,e) 
Numbers of CD45.1+OT-I cells in the blood, spleen and FTR tissues assessed 5 days post 
immunisation. The data are pooled from two independent experiments (n= 4-6 per 
experimental group). ***p<0.001 by one-way ANOVA, error bars show s.e.m. 
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Figure 5. Monocytes infiltrating the FRT express the CXCR3 ligand CXCL9 after skin 
immunisation. (a) Representative flow cytometry plots and summary bar graph of CXCL9 
expressed on CD45+ CD11b+ cells isolated from FRT tissue at day 7 after skin immunisation 
with Ad-CN54 gag via ID injection or MA application or left naive. (b,c) Representative 
histograms and bar graphs summarise CXCL9 expression among: (b) a gated 
CD45+Ly6C+CD11b+MHCII-CD11c- monocyte population and (c) a gated CD45+Ly6C-
CD11b+MHCII+CD11c+ dendritic cell population. Data are representative of three 
independent experiments (n=5 per experimental group). *p<0.05, **p<0.01 by one-way 
ANOVA, error bars show s.e.m. 
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Figure 6. Skin immunisation promotes the earl y recruitment of ILC1 and monocytes to 
the FRT. (a,b) Frequency of ILC1 (CD45+NK1.1+ CD3-) and monocytes 
(CD45+Ly6C+CD11b+MHCII-) in peripheral blood (a) and FRT tissue (b) at the indicated time 
points from naive or Ad-CN54 gag skin MA immunised mice for each time point  (c,d). 
Representative flow cytometry profile of CD69 expressed on ILC1 isolated from peripheral 
blood (c) or FRT tissue (d), 24 h after Ad-CN54 gag immunisation or from naive controls. 
Data are from three independent experiments (n=3-10 per group). *p<0.05, **p<0.01 by one-
way ANOVA, error bars show s.e.m. 
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Figure 7. Ad-vector bio-distributed after skin immunisation recruits group 1 ILCs and 
monocyte into the FRT. (a) Experimental design. Mice were immunised with Ad-CN54 gag 
by MA delivery to skin (1x109 vp) or by injection to the vaginal mucosa (i/vag) with 3.5x102 vp 
(equivalent to the bio-distributed Ad vector dose). Control mice were injected PBS (i/vag.).  
After 1 day, NK1.1+ CD3- (ILC1) and after 3 days (monocytes) were enumerated from 
peripheral blood and FRT tissues. (b) Frequency of Lin- NK1.1+ CD3- ILC1 in peripheral 
blood. (c) Frequency (left panel) and absolute number (right panel) of Lin- NK1.1+ CD3- ILC1 
in FRT. (d) Frequency of monocytes in peripheral blood. (e) Frequency (left panel) and 
absolute number (right panel) of monocytes cells in FRT. Data are from two independent 
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experiments (n =4-7 per experimental group). p>0.05 (ns),  *p<0.05, **p<0.01, ***p<0.001 by 
one-way ANOVA, error bars show s.e.m. 
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Figure 8. Recruitment of CD8+ T cells to the FRT requires group 1 ILCs and IFNγ  (a) 
The experimental design. Anti-NK1.1 antibody or PBS was injected i.p 1 day before and at 3, 
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6, 9 and 12 days after skin immunisation by MA with Ad-CN54 gag. (b,c) Frequency of 
Db/CN54 gag tet+ CD8+ T cells in peripheral blood (b) and FRT tissue (c) 14 days after 
immunisation. (d,e) Frequency of tet+ CD8+ T cells expressing CXCR3+ in peripheral blood 
(d) and FRT tissue (e) 14 days after immunisation.  Data (b,c,d,e) are from two independent 
experiments (n=4-8 per group). **p<0.01 by one-way ANOVA, error bars show s.e.m. (f) 
Flow cytometric analysis of CD45+Ly6C+CD11b+MHCII-CD11c- cells from each experimental 
group at 3 days post immunisation for CXCL9 (red histograms) and isotype control antibody 
staining (grey-filled histograms). (g) Summary graph showing CXCL9 expression from a 
gated CD45+Ly6C+ CD11b+MHCII-CD11c- monocyte population. Data are from two 
independent experiments (n=4-8 per group). *p<0.05, **p<0.01 by one-way ANOVA, error 
bars show s.e.m. (h) Experimental design for anti-IFNγ administration. WT or Rag1-/-  (Rag-/-) 
were injected i.p with anti-IFNγ antibody (500 µg) 1 day before and at day 0, 1, 2 and 3 
relative to skin immunisation with Ad-CN54 gag. Rag2-/-γc-deficient (Rag-/-γcnull/) were 
immunised with Ad-CN54 gag or left naive. (i) Representative flow cytometry profiles 
showing CXCL9 expression on monocytes (gated on CD45+Ly6C+ CD11b+MHCII-CD11c-) 
from the FRT of each treatment group at day 4 post immunisation. Data are of n=3 per 
group. *p<0.05, **p<0.01 by one-way ANOVA, error bars show s.e.m. (j) Summary bar 
graph showing frequency of CXCL9+ Ly6Chi monocytes in FRT tissue isolated from each 
experimental group. Data are from two independent experiments, (n=2-6 per group). 
***p<0.0001 by one-way ANOVA, error bars show s.e.m. 
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